Fasiglifam

1000413-72-8

1374598-80-7

2-[(3S)-6-{[4′-(3-methanesulfonylpropoxy)-2′,6′-dimethyl-[1,1′-biphenyl]-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl]acetic acid

3-Benzofuranacetic acid, 6-[[2′,6′-dimethyl-4′-[3-(methylsulfonyl)propoxy][1,1′-biphenyl]-3-yl]methoxy]-2,3-dihydro-, (3S)-

[(3S)-6-({2′,6′-Dimethyl-4′-[3-(methylsulfonyl)propoxy]-3-biphenylyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid

[(3S)-6-({2′,6′-Dimethyl-4′-[3-(methylsulfonyl)propoxy]-3-biphenylyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]essigsäure

Acide [(3S)-6-({2′,6′-diméthyl-4′-[3-(méthylsulfonyl)propoxy]-3-biphénylyl}méthoxy)-2,3-dihydro-1-benzofuran-3-yl]acétique

Fasiglifam

Fasiglifam

Fasiglifam

Fasiglifamum

GLP1W4JXAH

(2R)-2-aminopentanedioic acid;D-Glutamic Acid

(3S)-6-(2′ ,6′-dimethyl-4′-3-(methylsulfonyl)propoxybiphenyl-3-ylmethoxy)-2,3-dihydro-1-benzofuran-3-ylacetic acid

(3S)-6-2′,6′-dimethyl-4′-3-(methylsulfonyl)propoxy1,1′-biphenyl-3-ylmethoxy-2,3-dihydro-3-benzofuranacetic acid

(3S)-6-[[2′,6′-Dimethyl-4′-[3-(methylsulfonyl)propoxy][1,1′-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid

(S)-2-(6-((2′,6′-dimethyl-4′-(3-(methylsulfonyl)propoxy)-[1,1′-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid

2-[(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid

2YB

[(3s)-6-({2′,6′-Dimethyl-4′-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid

[(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid

D(−)-Glutamic acid

Fasiglifam;TAK 875;TAK875

fasiglifamum

FFAR1_HUMAN

FFAR1_MOUSE

Hepatic sodium/bile acid cotransporter

MC4R_RAT

Melanocortin receptor 4

MFCD18251445

NTCP_HUMAN

Sodium/bile acid cotransporter

TAK-875(0.5 H2O)

tak-875(fasiglifam)

фасиглифам

فاسيقليفام

法格列凡